GI events were the most common adverse effects, vast majority mild to moderate
Positive Signals For some, the expansion of GLP-1 options including non-injection formulations represents progress in making hunger and appetite-focused solutions more accessible
Lower back pain is not listed as a common or characteristic adverse effect in the FDA-approved prescribing information for semaglutide formulations (Ozempic, Wegovy, or Rybelsus)
Combined use may enhance digestive comfort and help users maintain consistency with semaglutide treatment
## Cost Comparison (March 2026 Estimates) | Medication | Brand Monthly | Compounded Monthly | |------------|--------------|-------------------| | Semaglutide | $900-1,300 | $200-400 | | Tirzepatide | $1,000-1,200 | $250-500 | | Retatrutide | N/A | $300-600 | | Liraglutide | $1,300-1,500 | $300-500 | Insurance coverage varies significantly by plan and indication